de Ory Fernando, Echevarría José Manuel, Kafatos George, Anastassopoulou Cleo, Andrews Nick, Backhouse Josephine, Berbers Guy, Bruckova Blazena, Cohen Daniel I, de Melker Hester, Davidkin Irja, Gabutti Giovanni, Hesketh Louise M, Johansen Kari, Jokinen Sari, Jones Lindsay, Linde Anika, Miller Elisabeth, Mossong Joël, Nardone Anthony, Rota Maria Cristina, Sauerbrei Andreas, Schneider François, Smetana Zahava, Tischer Annedore, Tsakris Athanassios, Vranckx Robert
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
J Clin Virol. 2006 Jun;36(2):111-8. doi: 10.1016/j.jcv.2006.01.017. Epub 2006 Apr 17.
The aim of the European Sero-Epidemiology Network (ESEN2) is to harmonise the serological surveillance of vaccine-preventable diseases in Europe.
To allow comparison of antibody prevalence in different countries by standardising results into common units.
For varicella zoster virus (VZV), a reference laboratory established a panel of 148 samples, characterised by indirect enzyme-immunoassay (ELISA), indirect immunofluorescence, and complement fixation test. Fifty-seven samples were also studied by the fluorescence antibody to membrane antigen test. The geometric mean of the antibody activity (GMAA) obtained from four ELISA determinations was used to characterise each sample of the panel as positive (GMAA: >100 mIU/ml), equivocal (GMAA: 50-100 mIU/ml) or negative (GMAA: <50 mIU/ml) for antibody to VZV (anti-VZV). Thirteen laboratories, using five different ELISA tests, tested the panel.
Agreement with the reference laboratory was above 85% in all cases, and the R(2) values obtained from regression analysis of the quantitative results were always higher than 0.87. Finally, the regression equations could be used to convert national values into a common unitage.
This study confirmed that results for anti-VZV obtained by different ELISA methods can be converted into common units, enabling the comparison of the seroprevalence profiles obtained in the participant countries.
欧洲血清流行病学网络（ESEN2）的目标是协调欧洲疫苗可预防疾病的血清学监测。
通过将结果标准化为通用单位，以便比较不同国家的抗体流行率。
对于水痘带状疱疹病毒（VZV），一个参考实验室建立了一组148个样本，通过间接酶免疫测定（ELISA）、间接免疫荧光和补体结合试验进行表征。57个样本还通过膜抗原荧光抗体试验进行了研究。从四次ELISA测定中获得的抗体活性几何平均值（GMAA）用于将该组中的每个样本表征为VZV抗体（抗VZV）阳性（GMAA：>100 mIU/ml）、可疑（GMAA：50 - 100 mIU/ml）或阴性（GMAA：<50 mIU/ml）。13个实验室使用五种不同的ELISA试验对该组样本进行了检测。
在所有情况下与参考实验室的一致性均高于85%，从定量结果的回归分析中获得的R²值始终高于0.87。最后，回归方程可用于将各国的值转换为通用单位。
本研究证实，通过不同ELISA方法获得的抗VZV结果可转换为通用单位，从而能够比较参与国获得的血清流行率概况。
